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Introduction: Ventricle Assist Device (VAD) implantation is an alternative treatment
for bridge-to-transplantation in heart failure therapy.Total Artiﬁcial Heart (TAH)
implantation is another branch of mechanical circulatory support (MCS).The main
advantage of this device is the possibility of both ventricular support.The current
indications for this therapy are biventricular failure, hypertrophic cardiomyopathy,
previous history of multiple mechanical valve replacement,malign arryhthmia
refractory to treatment, massive myocardial infarction with ventricular septal rupture.
In this study, our goal is to present the different examples of TAH implantation in
heart failure therapy.
Materials And Methods: Total Artiﬁcial Heart (SyncardiaCardiowest) consists of
two pump (70ml volume) running with pneumatic system and two vascular graft.
Implantation was performed with the excision of ventricle at the level of atrioven-
tricular valve. Vascular grafts was anastomosed to aorta and pulmonary artery. The
implantation of this device is limited to patients with body surface area greater than
1.7m2 and more than 12 cm sternal-spine distance. Case1: 58 years old, male, with the
diagnosis of idiopathic dilated cardiomyopathy, has been hospitalized for decom-
pansated heart failure. Patient showed signs of both left and right heart failure.
(LVEF20% RVEF:20%, TAPSE:9 mm on Echocardiography. Despite inotropic
support, patient developed cardiogenic shock. (INTERMACS level 1) TAH implan-
tation was performed emergently. Case 2: 40 years old male, with history of coronary
artery bypass and left ventricle aneurysmectomy, showed decompansation of heart
failure. Clinical ﬁndings and echocardiographic data showed biventricular heart
failure. (LVEF: 20%, RVEF 25%, TAPSE: 6mm) Despite inotropic support and IABP
implantation, patient had liver and renal failure. TAH was implanted urgently. Case 3:
Patient with the diagnosis of hypertrophic cardiomyopthy, was listed for heart
transplant. But patient developped an severe attack of malign ventricular arrhythmia
which requiring a battery change of ICD. Patient had decompansated heart failure.
Although he was at level of INTERMACS 4, TAH implantation was performed due to
arrhythmia.
Results: Three patient with different clinical picture of heart failure was treated
succesfully with TAH implantation. In all patients chest was kept open ﬁrst 3 days,
and than closed. One patient was reoperated for bleeding. One patient had an transient
ischemic attack without neurologic sequelae. Organ dysfunctions were completely
recovered in early postoperative period. All patients are discharged and monitored
outpatient without any symptoms of heart failure. D_ISCUSS_ION:The common
treatment for heart failure therapy with MCS, is LVAD implantation. TAH, which
recovers organ dysfunction with high and pulsatile blood ﬂow, is an important
alternative for heart transplant candiates with cardiogenic shock and other indications
before-mentioned.Electrophysiology–Ablation
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Background: Cardiac resynchronization therapy(CRT)is related with improved
morbidity and mortality in left bundle branch block(LBBB)with and without atrial
ﬁbrillation(AF). No clear data is present in non-LBBB with AF.
Methods: Patients with AF and CRT (LBBB and non-LBBB) requiring atrioven-
tricular node(AVN)ablation were assigned to AVN ablation and non-AVN ablation
groups. Primary end-points were composite of all-cause mortality or heart failure
hospitalization. Four-year follow-up was planned.
Results: A total of 82 patients with CRT were included. Of these, 38 (46%) had
LBBB with AF and 44 (54%) had non-LBBB with AF. Ablation was performed in 20JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORA(24%) patients with LBBB and in 22(27%) with non-LBBB. The mean age was 65
years. Males were 83%. Ischemic etiology was 51% and mean AF duration was 32
months. In all population the primary end-point of all cause mortality or heart failure
hospitalization was lower in AVN ablation patients compared with non-AVN ablation
patients (6.1% vs. 18.3%, p¼0.007), driven by reduction in both mortality (2.4% vs.
9.8%, p¼0.035) and hospitalization (6.1% vs. 15.9%, p¼0.024). In LBBB patients,
the primary end-point was also lower in AVN ablation patients compared with non-
AVN ablation patients (5.3% vs. 21.1%, p¼0.016), driven by reduction in both
mortality (0% vs. 10.5%, p¼0.026) and hospitalization (5.3% vs. 18.4%, p¼0.036). In
non-LBBB patients, the primary end-point was 6.8% and 15.9% in AVN ablation
group and non-AVN ablation group, respectively.However,this difference did not
reach a statistical signiﬁcance (p¼0.150) (Figure).
Conclusion: The morbidity and mortality beneﬁt of AVN ablation was demonstrated
in heterogeneous group of patients with or without LBBB and AF.Subgroup analysis
of patients with non-LBBB and AF did not, however, show the same beneﬁt.OP-101
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Background: Cryoballoon ablation of atrial ﬁbrillation (AF) is an effective therapy in
maintaining sinus rhythm. The procedure is mainly recommended for anti-arrhythmic
resistant cases. No randomized study is, however, present about cryoablation as ﬁrst
line therapy.
Aim: The aim is to compare cryoablation as ﬁrst line therapy with cryoablation after
drug resistance.
Methods: Consecutive patients (all-comers) with paroxysmal AF (PAF) planned for
catheter ablation were randomized to cryoballoon (Arctic Front Advance, Medtronic)
ablation as ﬁrst-line therapy without prior anti-arrhythmic drug use (n¼33) and cry-
oballoon (Arctic Front Advance, Medtronic) ablation after at least one anti-arrhythmic
drug resistance (n¼23). All patients were followed-up at least 12 months. Periodic
ambulatory Holter monitoring was performed to detect any recurrence at 1, 3, 6, 9, 12,
and every 6 months after 1 year.
Results: The median age was 49 years. Male was 66% and 7% of patients had dia-
betes and 34% had hypertension. The mean follow-up period was 185 months and
the mean procedural time was 598 minutes. The primary end-point of freedom from
AF was found to be statistically indifferent in both groups (78.8% for ﬁrst-line therapy
vs. 78.3% for after-drug therapy, p¼0.857) (ﬁgure).
Conclusion: Cryoballoon ablation as ﬁrst-line therapy is as effective as cryoballoon
ablation after anti-arrhythmic drug resistance in maintaining sinus rhythm.LS C45
MTHFR 677C>T polymorphism genotype and allel frequencies
AF patients
with stroke
(n:70)
Control
(n:70) P
n: % n: %
CC genotype 19 27.1 37 52.9 0.002
CT genotype 27 386. 20 28. 0.210
TT genotype 24 34.3 13 18.6 0.035
CT + TT genotypes
(Dominant genetic model)
51 72.9 33 47.1 0.002
T allel 75 53.6 46 32.9 0.006
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Background: Methyleletetrahydrofolate reductase (MTHFR) gene 677C>T mutation
in the gene coding for MTHFR, characterized by the replacement of cytosine with
thymidine, leads to reduced MTHFR activity and is associated with moderately
elevated homocysteine levels. MTHFR polymorphism has been proposed by some
studies to be also a thrombophilic risk factor for venous thrombosis and athero-
thrombosis. Atrial ﬁbrillation (AF) is the commonest sustained cardiac arrhythmia,
which confers a high risk of mortality and morbidity from stroke and thromboem-
bolism. We aimed to investigate MTHFR gene 677C>T mutation in patients with AF
who have had a stroke than in healthy controls.
Methods: MTHFR gene 677C>T mutation was analysed in 70 patients with non-
valvular AF who have had a stroke and 70 healthy individuals with no documented
episode of AF matched for age, race and sex. After DNA isolation, polymorphisms
were analyze using Polymerase Chain Reaction-Restriction Fragment Length Poly-
morphism methods. Distribution of the MTHFR 677 C>T mutation alles (allel C, allel
T) and genotypes (Normal (CC) genotype, heterozygous (CT) or homozygous (TT)
mutant genotype) were identiﬁed in study population. Demographic characteristics
and risk factors for AF and stroke were evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. Genotype and allel distribution of AF patients who have had a stroke and
control groups shown in the table. The frequency of CC normal genotype of the
MTHFR gene 677 C>T was signiﬁcantly lower in patients with AF patients who have
had a stroke group compared with control group (p<0,05). The frequency of TT
homozygous mutant genotype was signiﬁcantly higher in AF patients who have had
a stroke group than control (p<0,05). Between the two groups were compared
according to the dominant genetic model (CT + TT vs. CC), The number of patients
carrying at least one T mutant allele (CT + TT) were signiﬁcantly higher in AF
patients who have had a stroke group than control (p<0,05). With respect to allelic
distribution (C vs T, additive model), the frequency of the T allele was signiﬁcantly
higher in AF patients who have had a stroke (p<0,05).
Conclusions: In this study, our data suggest that the MTHFR gene 677C>T mutation
may be associated with AF patients who have had a stroke from other clinical risk
factors, but this should be conﬁrmed in a much larger series of patients. Screening for
this mutation may help in identifying patients at risk and in deciding the antith-
rombotic strategy.C46 JACC VOP-103
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Presence of Fragmented QRS and Its Relationship with Cardiac Functions in
Patients with Obstructive Sleep Apnea
Background: Obstructive Sleep Apnea (OSA) is associated with left ventricular
dysfunction because of myocardial inﬂammation and ﬁbrosis. Fragmented QRS
(fQRS) has also been associated with myocardial ﬁbrosis and heart failure. The value
of fQRS as an indicator of myocardial ﬁbrosis and heart failure in patents with OSA
has unknown.
Objective: In this study, we aimed to assess the relationship between OSA and fQRS
with cardiac function.
Methods: One hundred eighty eight patients underwent an overnight poly-
somnography were enrolled in the study. Thirty ﬁve patients were excluded from
study according to exclusion criteria. Patients divided into two groups; group 1 had
OSA and group 2 had not. FQRS was deﬁned to be notching in R or S wave, the
presence of additional R wave (R’) or fragmented R wave (more than one R’) at least
two consecutive derivation of 12 lead electrocardiograms. Left and right cardiac
functions were assessed by myocardial performance index (Tei index) and tricuspid
annular plane systolic excursion (Tapse), respectively. Multivariable regression
analysis was performed to assess the independent relationship between fQRS and
cardiac function in patients with OSA.
Results: Group 1 consisted of 121 patients (mean age 50.510) with OSA (26 mild,
31 moderate, 64 severe) and group 2 included 32 non-OSA patients (mean age
45.349). Baseline demographic features were similar such as gender (p¼0.71),
presence of hypertension (p¼0.47), presence of diabetes (p¼0.51), the usage of b-
blocker (p¼0.91), the usage of ACE inhibitor (p¼0.53) and the body mass index
(p¼0.11). FQRS was detected in 85 (70%) of OSA patients and 4 (12.5%) of non-
OSA. Left cardiac functions were impaired in patients with OSA than non-OSA
assessed by tei index (0.6132 vs 0.43.02 p¼0.001) but right cardiac function
assessed by tapse was not impaired (24.132.6 vs 23.72.6, p¼0.56). Also, in OSA
group, patients with fQRS had impaired left cardiac functions assessed by tei index
(p<0.001) than without fQRS but right cardiac function assessed by tapse was not
impaired (p¼0.792) than those without fQRS. In multivariable logistic analyze, left
ventricular Tei index (p<0.001), lowest nocturnal oxygen saturation (p¼0.018) and
left ventricular mass index (p¼0.003) were independently associated with fQRS in
patients with OSA.
Conclusions: Patients with OSA have frequent fQRS than those without OSA.
Severity of OSA is also associated with fQRS formation. FQRS is related with
impaired left ventricular function in this population.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
